Takuya Sho

Sapporo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 118 publications

Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.

Alcohol involvement may modify the association between previous hepatitis B virus infection and hepatocellular carcinoma risk in steatotic liver disease.

Journal: Journal of gastroenterology
Published: May 05, 2026

Reticulated Erythematous Mucinosis Preceding the Clinical Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Reticulated Erythematous Mucinosis Preceding the Clinical Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Journal: The Journal of dermatology
Published: March 26, 2026

Competing risks of treatment discontinuation of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Competing risks of treatment discontinuation of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Journal: JHEP reports : innovation in hepatology
Published: March 10, 2026

Effects of partial splenic embolization and portosystemic shunt occlusion on portal venous hemodynamics using 4D flow MRI.

Effects of partial splenic embolization and portosystemic shunt occlusion on portal venous hemodynamics using 4D flow MRI.

Journal: Abdominal radiology (New York)
Published: March 08, 2026

HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapy.

HBsAg glycan isomer predicts on-treatment HBsAg decline in low-HBsAg chronic hepatitis B on nucleos(t)ide therapy.

Journal: Virology journal
Published: February 03, 2026

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients.

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: December 12, 2025

Corticosteroid rescue of immune checkpoint inhibitor-induced hepatitis triggers HCV reactivation in HCV-related HCC.

Corticosteroid rescue of immune checkpoint inhibitor-induced hepatitis triggers HCV reactivation in HCV-related HCC.

Journal: European journal of cancer (Oxford, England : 1990)
Published: November 22, 2025

Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.

Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study.

Journal: The Journal of infection
Published: November 21, 2025

Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.

Serum fibroblast growth factor 21 is a novel biomarker of cachexia in chronic liver disease.

Journal: Frontiers in nutrition
Published: October 23, 2025

Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.

Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.

Journal: Hepatology international
Published: October 22, 2025

Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.

Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.

Journal: Journal of cachexia, sarcopenia and muscle
Published: October 20, 2025

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.

Journal: Scientific reports
Published: September 19, 2025
Showing 1-12 of 118

Last Updated: 09/26/2026